Señales en vivo de KNSA | Maximiza tus Ganancias con Getagraph.com

VENDER 117251 min ago

@ $19.84

Emitido: 13 feb 2024 @ 15:47

Retorno: 1.21%

Señal anterior: feb 12 - 13:31

Señal anterior: Comprar

Retorno: -4.34 %

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	396 335
Volumen promedio	387 666
Capitalización de mercado	1.42B
EPS	$0 ( 2024-04-23 )
Próxima fecha de ganancias	( $-0.140 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	154.46
ATR14	$0.0130 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-26	Ragosa Mark	Buy	991	Class A Common Share
2024-04-26	Ragosa Mark	Sell	509	Class A Common Share
2024-04-26	Ragosa Mark	Buy	991	Restricted Share Unit
2024-04-04	Patel Sanj K	Buy	129 750	Share Option
2024-04-08	Patel Sanj K	Buy	9 992	Class A Common Share

INSIDER POWER
24.48
Last 100 transactions
Buy: 574 001 \| Sell: 364 351

Volumen Correlación

Largo: 0.31 (neutral)

Corto: -0.29 (neutral)

Signal:(73.338) Neutral

Kiniksa Pharmaceuticals Correlación

10 Correlaciones Más Positivas
CSSEP	0.955
EVLO	0.953
GOOD	0.952
SIRI	0.951
ORPH	0.95
ALXO	0.95
NAKD	0.95
AYTU	0.949
LSXMA	0.948
LSXMK	0.948

10 Correlaciones Más Negativas
CPAQ	-0.966
HERA	-0.966
TBSA	-0.965
AGGR	-0.965
LGAC	-0.965
ACQR	-0.964
APXI	-0.964
KAII	-0.964
FICV	-0.963
HERAU	-0.963

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kiniksa Pharmaceuticals Correlación - Moneda/Commodity

0.64
( weak )

0.63
( weak )

0.59
( weak )

0.54
( weak )

-0.67
( moderate negative )

Kiniksa Pharmaceuticals Finanzas

Annual	2023
Ingresos:	$270.26M
Beneficio Bruto:	$179.22M (66.31 %)
EPS:	$0.200

FY	2023
Ingresos:	$270.26M
Beneficio Bruto:	$179.22M (66.31 %)
EPS:	$0.200

FY	2022
Ingresos:	$220.18M
Beneficio Bruto:	$173.21M (78.67 %)
EPS:	$2.64

FY	2021
Ingresos:	$38.54M
Beneficio Bruto:	$29.44M (76.39 %)
EPS:	$-2.30

Financial Reports:

No articles found.

Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Actualizaciones en tiempo real para Kiniksa Pharmaceuticals [KNSA]

Upcoming Earnings Alert